Woestmann, Fabian 
ORCID: 0000-0002-5928-1746, Strubl, Sebastian, Farowski, Fedja ORCID: 0000-0002-6730-0038, Arjune, Sita ORCID: 0000-0002-6121-4614, Tsakmaklis, Anastasia ORCID: 0000-0001-5380-3614, Todorova, Polina ORCID: 0000-0002-4728-224X, Späth, Martin R. ORCID: 0000-0002-1624-0055, Brodesser, Susanne ORCID: 0000-0001-5631-0663, Baar, Till ORCID: 0000-0002-6744-1463, Grundmann, Franziska ORCID: 0000-0002-5766-7477, Vehreschild, Maria J.G.T. ORCID: 0000-0003-0446-3224 and Müller, Roman-Ulrich ORCID: 0000-0001-6910-0745
(2025).
The Gut Microbiome in Autosomal Dominant Polycystic Kidney Disease. A Cross-Sectional Study.
Kidney360, 6 (11).
pp. 1906-1917.
American Society of Nephrology.
ISSN 2641-7650
![[thumbnail of kidney360-6-1906.pdf]](http://kups.ub.uni-koeln.de/style/images/fileicons/application_pdf.png "kidney360-6-1906.pdf") |
PDF
kidney360-6-1906.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution Non-commercial No Derivatives. Download (962kB) |
Abstract
Background: Changes in gut microbiota signatures have been associated with CKD and nephrolithiasis and may thus be a factor explaining variability of outcome in autosomal polycystic kidney disease (ADPKD). We aimed to characterize the intestinal microbiome in a cross-sectional study of patients with ADPKD and to explore the potential effect of microbiome signatures on polycystic kidney disease progression. Methods: This observational cross-sectional pilot study recruited 25 patients from the German ADPKD Tolvaptan Treatment Registry patient cohort and 12 healthy, age- and sex-matched control participants. The gut microbiome was analyzed by 16S ribosomal RNA gene profiling of stool samples. Bacteria-derived serum uremic toxins were measured using liquid chromatography coupled with tandem mass spectrometry. Microbiome data were correlated with age, kidney function, and markers of polycystic kidney disease progression like Mayo classification and arterial hypertension <35 years of age. Results: Patients with ADPKD displayed a significantly decreased abundance of Actinobacteria including probiotic Bifidobacteriaceae and significantly increased abundance of Enterobacteriaceae. Those findings were independent of kidney function. Most notably, Streptococcaceae were significantly overrepresented in patients with Mayo classes 1D and 1E compared with 1A–1C. In addition, early onset of hypertension (<35 years of age) was associated with an increased abundance of Proteobacteria and a decreased abundance of Tannerelleaceae. Furthermore, patients with ADPKD revealed an increased abundance of Peptococcaceae with increasing age and declining kidney function. Finally, serum uremic toxin levels were significantly increased in patients with ADPKD, highly correlating with eGFR. Conclusions: This pilot study suggests relevant changes in gut microbiota signatures of patients with ADPKD, which might be associated with rapid disease progression. These findings indicate that composition of the gut microbiota could potentially contribute to disease progression of ADPKD and the individual disease variability. Further investigation is warranted to assess the gut microbiota as a potential therapeutic target in ADPKD.
https://orcid.org/0000-0002-5928-1746Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |